- Home
- JANX vs CDNL Comparison
JANX vs CDNL Comparison
Compare JANX & CDNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JANX | CDNL |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 888.6M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | JANX | CDNL |
|---|---|---|
| Price | $16.71 | $13.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | $36.24 | ★ $49.75 |
| AVG Volume (30 Days) | 746.1K | ★ 1.0M |
| Earning Date | 11-05-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | $10,000,000.00 | ★ $456,045,369.00 |
| Revenue This Year | $194.24 | $95.00 |
| Revenue Next Year | N/A | $20.19 |
| P/E Ratio | ★ N/A | $25.87 |
| Revenue Growth | N/A | ★ 44.69 |
| 52 Week Low | $12.12 | $13.51 |
| 52 Week High | $35.34 | $96.40 |
Technical Indicators
Market Signals| Indicator | JANX | CDNL |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 21.17 |
| Support Level | $15.83 | N/A |
| Resistance Level | $19.16 | $28.07 |
| Average True Range (ATR) | 0.91 | 2.06 |
| MACD | -0.05 | -0.27 |
| Stochastic Oscillator | 16.32 | 4.90 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About CDNL Cardinal Infrastructure Group Inc. Class A Common Stock
Cardinal Infrastructure Group Inc provides a comprehensive suite of infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. The company provides wet utility installations (water, sewer, and stormwater systems), as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. It derives all revenue in the United States of America from construction projects based in North Carolina and South Carolina.